Case Report
Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia
Table 1
Characteristics of the current and previously published cases of myelodysplastic syndrome with acquired elliptocytosis.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FAB and 2016 WHO classifications were determined using data from published cases. Where data are not sufficient to determine classification, the possible classifications based on available information are shown. IPSS-R score calculated using data from published cases. Where insufficient data is available, the range of possible scores is presented with missing information noted in parentheses. General abbreviations: ANC: absolute neutrophil count, MPN: myeloproliferative neoplasm, NA: not applicable, NR: not reported, FAB abbreviations: RA: refractory anemia, RA-EB: refractory anemia with excess blasts, RARS: refractory anemia with ring sideroblasts. WHO 2016 abbreviations: MDS-SLD: MDS with single lineage dysplasia, MDS-MLD: MDS with multilineage dysplasia, MDS-MLD-RS: MDS with multilineage dysplasia and ring sideroblasts, MDS-EB-1/2: MDS with excess blasts 1 or 2, MDS-U: MDS unclassifiable, AML: acute myeloid leukemia, CMML: chronic myelomonocytic leukemia, CCUS: clonal cytopenia of unclear significance. One case not included in this report was classified as MDS/MPN when published in 2008 but would now be classified as AML based on 25% blasts on bone marrow biopsy. †Molecular data available for this case; reported findings included no mutation in JAK2, CALR, or MPL. |